Fortuitous Discovery of Asymptomatic Homozygous Antithrombin Deficiency: A Rare p.Leu131Phe Heparin‐Binding Site Mutation: A Case Report
ABSTRACT Homozygous Type II heparin‐binding site antithrombin deficiency is a rare inherited thrombophilia associated with a high risk of early thrombotic events. We report a 6‐week‐old infant homozygous for the SERPINC1 c.391C>T (p.Leu131Phe) variant (Antithrombin Budapest III), with markedly reduced antithrombin activity (12%). Despite this high‐risk genotype, the patient remains asymptomatic without thrombotic or vascular abnormalities and has not required anticoagulant treatment to date. This case highlights the phenotypic heterogeneity of homozygous antithrombin Budapest III deficiency and the importance of genetic diagnosis, family screening, and careful long‐term follow‐up. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission
Authors
- Laurence Rozen (ORCID: https://orcid.org/0000-0003-4345-7409)
- Christelle Orlando (ORCID: https://orcid.org/0000-0003-2163-8778)
- Anne Demulder (ORCID: https://orcid.org/0000-0002-5272-8939)
- Sara Cherkaoui (ORCID: https://orcid.org/0009-0007-8947-7137)
- Laurence Dedeken (ORCID: https://orcid.org/0000-0001-7829-6428)
- Joanna Simar
Institutions
- Université Libre de Bruxelles (BE)
- Vrije Universiteit Brussel (BE)
- Clinique Saint Pierre (BE)
- Centre Hospitalier Universitaire Brugmann (BE)
- Queen Fabiola Children's University Hospital (BE)
- Universitair Ziekenhuis Brussel (BE)
Publication Details
- Journal
- eJHaem
- Published
- 2026-11-07
- DOI
- https://doi.org/10.1002/jha2.70398
- Primary Topic
- Blood Coagulation and Thrombosis Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00